{
    "Trade/Device Name(s)": [
        "Quo-Test A1c System"
    ],
    "Submitter Information": "EKF-diagnostic GmbH",
    "510(k) Number": "K180509",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JJE"
    ],
    "Summary Letter Date": "November 2, 2018",
    "Summary Letter Received Date": "November 5, 2018",
    "Submission Date": "February 13, 2019",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.2160"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay",
        "Discrete photometric chemistry analyzer for clinical use"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Glycated hemoglobin (HbA1c)"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Quo-Test Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Boronate affinity fluorescence quenching",
        "Photometric measurement",
        "Fluorimetric measurement"
    ],
    "Methodologies": [
        "Quantitative determination of HbA1c"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay",
        "Cartridge",
        "Control Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Quo-Test A1c System, an in vitro device for quantitative determination of glycated hemoglobin (HbA1c) in venous whole blood using boronate affinity fluorescence quenching.",
    "Indications for Use Summary": "Intended for the in vitro quantitative determination of glycated hemoglobin (%HbA1c) in venous whole blood samples for monitoring long-term glycemic control in individuals with diagnosed diabetes mellitus; not for screening, diagnosis of diabetes, or neonatal use; for professional use in clinical laboratories.",
    "fda_folder": "Hematology"
}